by Victoria Radke | Jun 15, 2021
The U.S. Food and Drug Administration (FDA) has approved StrataGraft as a treatment for adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Typically, thermal burns are treated by autograft which...
by Victoria Radke | Jun 15, 2021
Amy Pooler, PhD, Vice President and Head of Neuroscience at Sangamo Therapeutics, discusses the company’s recent presentation on the use of zinc finger protein technology as a potential treatment for amyotrophic lateral sclerosis (ALS). ALS, also known as Lou...
by Victoria Radke | Jun 11, 2021
The U.S. Food and Drug Administration (FDA) has approved the expanded use of ravulizumab (brand name: ULTOMIRIS) to include children (one month of age and older) and adolescents with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, life-threatening blood...
by Victoria Radke | Jun 7, 2021
The U.S. Food and Drug Administration (FDA) has granted approval to Prometic Biotherapeutics for plasminogen (brand name: Ryplazim) as a treatment for plasminogen deficiency type 1. This is the first FDA approved treatment for this condition. Plasminogen deficiency...
by Victoria Radke | May 28, 2021
The U.S. Food and Drug Administration (FDA) has approved infigratinib (brand name: Trusetiq for the treatment of previously treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 gene fusion or rearrangement. CCA is a rare cancer that forms...
